Ebola Outbreak in DR Congo Reaches 600 Deaths Amid Spread Concerns
The Ebola outbreak in the Democratic Republic of Congo has escalated, with the death toll reaching 600 and nearly 1,800 reported infections as of early July 2026. The outbreak is caused by the Bundibugyo strain of the Ebola virus, for which no approved vaccine or proven specific treatment currently exists. According to a government report, 1,759 cases have been confirmed, with 51 new infections and 20 deaths recorded in the 24 hours prior to the report. The World Health Organization (WHO) has warned that the outbreak continues to expand, while local healthcare systems face shortages of equipment, overwhelmed treatment centers, and insecurity due to armed groups operating in affected regions.
New concerns have arisen following two suspected cases detected in Kisangani, located in the Tshopo province. One case is linked to the outbreak’s epicenter in the Ituri province, but the other has no clear geographic connection yet. Kisangani’s position on the Congo River makes it a key transport hub, raising fears that increased movement of people and goods could complicate contact tracing and create new transmission chains. Medical teams have begun screening family members, caregivers, and contacts of suspected patients.
The outbreak, declared on May 15, has spread across Ituri, North Kivu, and South Kivu provinces, areas long affected by conflict, displacement, and damaged infrastructure. Many villages are remote and difficult to access, complicating medical response efforts. The Bundibugyo strain differs from the Zaire strain targeted by existing Ebola vaccines, limiting the use of ring vaccination strategies that have previously helped contain outbreaks. Experimental vaccines and treatments are under evaluation but are not yet widely available.
Ebola transmits through direct contact with the blood or bodily fluids of infected individuals, often during medical care without protective gear, home caregiving, or burial rituals. Symptoms begin with fever, severe weakness, muscle and throat pain, progressing to vomiting, diarrhea, abdominal pain, rash, and organ dysfunction. Early treatment with fluids, electrolyte replacement, oxygen, and infection control improves survival chances. However, fear and mistrust of authorities and healthcare workers hinder timely reporting and isolation of cases. Local outreach efforts involve community leaders and survivors to encourage cooperation.
Healthcare workers face heightened risks due to shortages of gloves, protective suits, disinfectants, and isolation equipment. Strikes and delayed salaries further impair patient monitoring and treatment center operations. Cross-border population movements have prompted neighboring countries like Uganda to increase traveler screening and healthcare staff training. Temperature checks alone are insufficient during incubation periods, necessitating detailed exposure histories.
In Israel, two returning travelers from Congo were hospitalized on suspicion of Ebola but tested negative. No confirmed Ebola cases have been reported in Israel to date.
